Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitral Stenosis I: Introduction

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Semi-Automated Computational Identification of Fibrosis for Enhanced Histopathological Decision Support.

Journal of imaging·2026

Same author

CMR-Derived Global Longitudinal Strain and Left Ventricular Torsion as Prognostic Markers in Dilated Cardiomyopathy.

Journal of cardiovascular development and disease·2025

Same author

CMR-Derived Strain and Torsion Reveal Subclinical Dysfunction in Hypertrophic Cardiomyopathy: A Prospective Case-Control Study.

Biomedicines·2025

Same author

A Non-Invasive Approach to Pulmonary Hypertension.

Journal of clinical medicine·2025

Same author

Cardiac Magnetic Resonance Imaging in the Evaluation of Functional Impairments in the Right Heart.

Diagnostics (Basel, Switzerland)·2024

Same author

Evaluating the Clinical Utility of Left Ventricular Strains in Severe AS: A Pilot Study with Feature-Tracking Cardiac Magnetic Resonance.

Biomedicines·2024

Search research articles

Related Experiment Video

Updated: Apr 13, 2026

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Published on: April 15, 2020

Soluble ST2 in Ventricular Dysfunction.

Silvia Lupu¹, Lucia Agoston-Coldea¹

¹Department of Cardiovascular Disease and Transplant Institute, University of Medicine and Pharmacy of Targu Mures, Targu Mures, Romania; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Advances in Clinical Chemistry

|May 3, 2015

Summary

New biomarkers like soluble ST2 are needed for accurate heart failure diagnosis and prognosis, especially with comorbidities. Current methods using B-type natriuretic peptides have limitations, necessitating further research into novel markers.

Keywords:

Biomarker Dyspnea Heart failure ST2 Ventricular dysfunction Ventricular remodeling

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Apr 13, 2026

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Published on: April 15, 2020

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Area of Science:

Cardiology
Biomarker Research
Molecular Biology

Background:

Heart failure is a prevalent condition with significant morbidity, mortality, and healthcare costs.
Current management relies on B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide biomarkers, which have limitations in accuracy and prognostic assessment, particularly with comorbidities.
There is a need for refined diagnostic and risk stratification tools in heart failure management.

Purpose of the Study:

To provide an overview of the currently available data on soluble ST2.
To explore the potential role of soluble ST2 as a novel biomarker in heart failure.

Main Methods:

Review of existing scientific literature and clinical studies on soluble ST2.
Analysis of data regarding the secretion of soluble ST2 in response to cardiac strain.
Evaluation of preliminary findings on the diagnostic and prognostic value of soluble ST2.

Main Results:

Soluble ST2 is a peptide from the interleukin-1 receptor family.
It is secreted by cardiomyocytes and cardiac fibroblasts under mechanical strain.
Preliminary results suggest soluble ST2 may offer improvements over current biomarkers, but more comprehensive studies are required.

Conclusions:

Soluble ST2 shows promise as a novel biomarker for heart failure.
Further extensive research is essential to fully establish its clinical utility in managing heart failure patients.
Refining diagnosis and prognosis in heart failure may be enhanced by novel biomarkers like soluble ST2.